Can Anagrelide be used for essential thrombocythemia?

Anagrelide (Anagrelide) can be used to treat essential thrombocythemia (essential thrombocythemia, ET). Idiopathic thrombocythemia is a myeloproliferative disorder characterized by persistently elevated platelet counts that may lead to complications such as thrombosis and bleeding.

Anagrelide is a selective inhibitor of platelet production that reduces platelet counts by inhibiting the process of platelet production. It reduces the production and release of platelets by inhibiting the activity of phosphonucleotide cyclase (phosphodiesterase).

Anagrelide is widely used in the treatment of idiopathic thrombocythemia, especially in patients who are intolerant or refractory to other treatments. It can effectively lower platelet counts, reduce the risk of blood clots and bleeding, and help control the condition.

However, drug selection for the treatment of essential thrombocythemia should be evaluated and determined based on the patient's specific circumstances, disease severity, and drug tolerability, among other factors. It is important to consult your doctor before using anagrelide or any other medication and follow your doctor's advice and prescriptions. The doctor will develop the most appropriate treatment plan for the patient based on his or her individual condition and needs.

Anagrelide is not yet on the market in China, so patients cannot purchase it domestically and need to purchase the drug through overseas channels. Anagrelide only has the original drug. Outside the mainland, there is the Hong Kong version of the original drug and the foreign Turkish original drug. The price is around 1280 yuan.